Atlas Trials

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome

Clinical trial NCT01243476 · COMPLETED

Trial details

NCT number
NCT01243476
Sponsor
Fundación General de la Universidad de Salamanca
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Myelodysplastic Syndrome
Start date
2010-01-01
Primary completion
2022-06-06
Enrollment
61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.